Trending: AstraZeneca Posts 4Q Profit, Covid-19 Vaccine Sales Decline
09 February 2023 - 11:01PM
Dow Jones News
1130 GMT - AstraZeneca PLC is among the most mentioned companies
across news items over the past 12 hours, according to Factiva
data, after the company posted a swing to fourth-quarter profit
despite a dip in revenue which was mostly due to declining sales of
its Covid-19 vaccine. The Anglo-Swedish pharma major posted net
profit of $901 million compared with a loss of $347 million in the
fourth quarter of 2021, when it took a hit from charges related to
the acquisition of Alexion Pharmaceuticals. Profit beat analysts'
expectations of $819 million. Revenue declined in the quarter to
$11.21 billion from $12.01 billion in the fourth quarter of 2021,
AstraZeneca said, and product sales fell to $10.80 billion from
$11.50 billion the year prior. Analysts had expected revenue to be
$11.25 billion in the quarter. Lower sales of Covid-19 vaccine
Vaxzevria affected total sales in the fourth quarter, and the
company said that revenue grew 17% when excluding the vaccine. Dow
Jones & Co. owns Factiva. ( cecilia.butini@wsj.com)
(END) Dow Jones Newswires
February 09, 2023 06:46 ET (11:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024